Last reviewed · How we verify
Aromatase inhibitor (aromatase-inhibitor)
Aromatase inhibitor, Pfizer Inc., blocks the enzyme aromatase to convert androgens into estrogens, primarily used in hormone receptor-positive breast cancer treatment in postmenopausal women. This class of drugs can also be used in premenopausal women with ovarian suppression therapy and in men for conditions like gynecomastia and hormone-sensitive cancers. Aromatase inhibitors are a key treatment option for hormone receptor-positive breast cancer, offering a targeted approach to estrogen reduction. The commercial significance of aromatase inhibitors lies in their high revenue, with $21.2B in sales. Pipeline developments in this area focus on improving efficacy and reducing side effects. Clinical differentiation comes from their ability to selectively target the aromatase enzyme, minimizing impact on other bodily processes.
At a glance
| Generic name | aromatase-inhibitor |
|---|---|
| Sponsor | Pfizer |
| Drug class | Aromatase inhibitor |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Adjuvant treatment of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis
- Treatment of advanced breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative disease
- Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
- Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer
Common side effects
Drug interactions
- Warfarin
- Phenytoin
- Rifampicin
- Phenobarbital
- Carbamazepine
- St. John's Wort
- Tamoxifen
- Estrogen-containing medications
- CYP3A4 inducers
Key clinical trials
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (PHASE3)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- Oral Aromatase Inhibitors Modify the Gut Microbiome
- A Study of LY4257496 in Participants With Cancer (OMNIRAY) (PHASE1)
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) (PHASE2)
- An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aromatase inhibitor CI brief — competitive landscape report
- Aromatase inhibitor updates RSS · CI watch RSS
- Pfizer portfolio CI